What this pack is
Plendil is the brand name in this record; felodipine is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
PlendilGeneric namefelodipine
Mainland China pack-name cue波依定®Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
The FDA 2012 historical label describes felodipine as a dihydropyridine calcium-channel blocker acting mainly at voltage-dependent calcium channels in vascular smooth muscle. This helps explain label wording; it does not determine anyone's diagnosis, suitability, effect, tablet count, co-use or switching.
Read source: United States ↗Historical public record · reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 波依定®
- International brand name
- Plendil
- Source-scoped market brand names
- 波依定 · Mainland China (dated government public record)Source-scoped evidence ↗A 2022 Jiangyin government medicine-price record lists 波依定 as AstraZeneca felodipine sustained-release tablets in 2.5 mg and 5 mg strengths. It supports only a dated Chinese trade-name, generic-name, modified-release-form and strength cue; it does not replace a current NMPA approval, leaflet, exact-pack, stock or sale-eligibility check.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- felodipine
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
Mainland China trade-name search cue:波依定®. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
3 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · FDA U.S. historical label (revised Oct 2012)
Felodipine 2.5 mg per tablet; 100-tablet bottle (historical label text)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0186-0450-58
- Form and route
- felodipine extended-release oral tablet · oral
- felodipine
- 2.5 mghistorical labelled amount per tablet; not an individual tablet count or adjustment instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- light reddish-brown · round biconvex tablet · imprint 450 / PLENDIL
United States label · FDA U.S. historical label (revised Oct 2012)
Felodipine 5 mg per tablet; 100-tablet bottle (historical label text)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0186-0451-58
- Form and route
- felodipine extended-release oral tablet · oral
- felodipine
- 5 mghistorical labelled amount per tablet; not an individual tablet count or adjustment instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- pink · round biconvex tablet · imprint 451 / PLENDIL
United States label · FDA U.S. historical label (revised Oct 2012)
Felodipine 10 mg per tablet; 100-tablet bottle (historical label text)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0186-0452-58
- Form and route
- felodipine extended-release oral tablet · oral
- felodipine
- 10 mghistorical labelled amount per tablet; not an individual tablet count or adjustment instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- reddish-brown · round biconvex tablet · imprint 452 / PLENDIL
PACKAGE-VISUAL STATUS
Historical label text was reviewed, but no one-to-one official package image was retained, so no package visual is shown
This dossier retains only PLENDIL, felodipine extended-release tablets, three historical NDCs, strengths and bottle text from the FDA 2012 historical label, which explicitly may not be the latest approved label. No retail image, image without a specific strength/NDC match or another-market image is presented as an exact original-brand package, so no package visual is shown.
LABEL READING · NOT A PRESCRIPTION
PLENDIL label reading: 2.5, 5 and 10 mg identify historical extended-release tablets; they do not answer “how many tablets”
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module reads only PLENDIL, felodipine extended-release tablets, three historical NDCs, labelled amount per tablet and bottle text in an FDA 2012 U.S. historical label. The document explicitly may not be the latest approved label; this page provides no individual tablet count, initiation, stopping, switching, co-use or purchase plan.
- Check PLENDIL, felodipine, extended-release tablet, actual strength, NDC and target market together. The 2.5, 5 and 10 mg figures are historical labelled amounts per tablet, not how many tablets anyone should use, and they cannot self-convert another brand, form or market product.
- The historical label says the extended-release tablets should be swallowed whole and not crushed or chewed. It does not replace the current leaflet for an actual pack; for splitting, swallowing difficulty, missed use, adjustment or switching, take the current pack, prescription and complete medicine list to a pharmacist or prescribing team.
- The historical label lists CYP3A4-related medicines and grapefruit as review cues and notes the need for more careful review with older age, multiple medicines or hepatic context. It is not a list for self-stopping, adding, spacing or replacing any medicine; have a professional review the exact product and complete medicine list.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkFDA · United States · Regulatory product record or label archive · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeFDA: PLENDIL (felodipine) U.S. historical label (revised Oct 2012; the document states that it may not be the latest approved label) ↗Historical public record · reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Plendil (felodipine). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Plendil is the brand in this record and felodipine is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
HOW IT WORKS · NOT A TREATMENT PLAN
How felodipine works: the historical label identifies a dihydropyridine calcium-channel blocker
- “Calcium-channel blocker” is a mechanism class, not evidence that all related medicines, the same generic name or similar blood-pressure medicines can be self-replaced, combined or milligram-converted.
- “Acts mainly in vascular smooth muscle” also does not explain the cause of a blood-pressure reading, dizziness, chest symptoms or another concern, and cannot decide continuation, stopping or switching. With an acute serious concern, prioritise local urgent medical care.
- Historical mechanism material does not replace the current leaflet for an actual pack. If multiple cardiovascular medicines, OTC products or supplements are involved, have a pharmacist or prescribing team review the exact products, target market and complete medicine list item by item.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- FDA: PLENDIL (felodipine) U.S. historical label (revised Oct 2012; the document states that it may not be the latest approved label) ↗Historical public record · reviewed 2026-08-20
- Jiangyin Municipal Government: 2022 medicine-price record listing the Bo Yi Ding trade name / felodipine sustained-release tablets (dated name cue) ↗reviewed 2026-08-31
SOURCE-TRACEABLE ARCHIVE
Plendilfelodipine
This page links to public primary-source material for Plendil. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
FDA label archive version
This page links the 2012-10 historical label FDA label archive as a traceable reading entry point. Current labeling, strength, indication and safety information require separate verification against the target market’s current document.
FDA: PLENDIL historical U.S. label (revised 2012-10) ↗
MARKET SCOPE
Market-record boundary
United States
Public label archive linkedOnly the FDA document listed on this page is linked.
Mainland China, EU, Japan
Market record not establishedNo local approval, holder, strength, supply or sale-eligibility conclusion is inferred from the U.S. label archive.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
Mainland China trade-name search cue: 波依定®
This cue helps read packaging and search official records. It does not establish current approval, holder, strength, originator relationship, supply or sale eligibility. Open historical reference ↗
RECORD FAQ
Record questions
Does a label archive represent current product information?
Not automatically. The archive locates a source; each point needs verification against the target market’s current official label.
Why are price and originator/generic conclusions not shown?
Those conclusions require separately complete and human-reviewed product, dosage-form, strength, pack, market, date and primary-record fields; one label file is insufficient.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.